Nabriva Therapeutics - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsNabriva Therapeutics

Nabriva Therapeutics(NBRV)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Xenleta	Lefamulin	2020-07-27	2028-2031	Community-acquired infections , Bacterial pneumonia

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

healthy volunteers/patients

,

,

cystic fibrosis

,

,

communicable diseases

,

bacterial infections

,

bacterial skin diseases

,

mycoplasma infections

,

pleuropneumonia

,

mycoplasma genitalium

,

,

multiple drug resistance

,

pseudomonas infections

,

disease resistance

,

bacterial pneumonia

,

,

,

urinary bladder neoplasms

,

urologic surgical procedures

,

colonic neoplasms

,

,

neonatal sepsis

,

ulcerative colitis

,

,

,

healthy volunteers/patients

,

,

,

escherichia coli infections

,

,

,

febrile neutropenia

,

,

,

,

urinary tract infections

,

communicable diseases

,

,

,

bacterial infections

,

,

,

intraabdominal infections

,

,

,

,

cystic fibrosis

,

,

healthcare-associated pneumonia

,

bacterial endocarditis

,

asymptomatic diseases

,

microbial drug resistance

,

infectious arthritis

,

prosthesis-related infections

,

,

,

prostatic neoplasms

,

hospitalization

,

graft rejection

,

neurogenic urinary bladder

,

ventilator-associated pneumonia

,

antibiotic prophylaxis

,

gram-negative bacterial infections

,

,

,

,

,

,

,

hyperaldosteronism

,

pulmonary arterial hypertension

,

,

sleep initiation and maintenance disorders

,

cardiac arrhythmias

,

respiratory tract infections

,

staphylococcal infections

,

,

bacterial meningitis

,

,

coronavirus infections

,

,

blood coagulation disorders

,

mucocutaneous lymph node syndrome

,

hyperphosphatemia

,

,

,

bronchopulmonary dysplasia

,

adrenal insufficiency

,

,

hemostatic disorders

,

,

coagulation protein disorders

,

attention deficit disorder with hyperactivity

,

chronic renal insufficiency

,

kidney diseases

,

migraine disorders

,

,

,

,

,

methicillin-resistant staphylococcus aureus

,

,

,

,

,

general anesthesia

,

,

,

,

central nervous system infections

,

neuromuscular blockade

,

,

,

cytomegalovirus retinitis

,

adenoviridae infections

,

port-wine stain

,

,

,

capillary hemangioma

,

,

bipolar disorder

,

autistic disorder

,

,

,

treatment-resistant schizophrenia

,

potassium deficiency

,

,

bacterial skin diseases

,

,

soft tissue infections

,

,

infectious bone diseases

,

,

,

central nervous system bacterial infections

,

urologic diseases

,

enterobacteriaceae infections

,

drug monitoring

,

Sodium chloride

healthy volunteers/patients

,

,

,

allergic rhinitis

,

,

allergic rhinitis seasonal

,

,

,

pulmonary eosinophilia

,

prostatic neoplasms

,

castration-resistant prostatic neoplasms

,

migraine disorders

,

sleep wake disorders

short bowel syndrome

,

,

,

,

,

,

,

bacterial conjunctivitis

,

,

,

cataract extraction

,

intravitreal injections

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use